Premium
P2‐059: Increased glutamate/N‐acetylaspartate in the hippocampus after galantamine treatment in Alzheimer's disease
Author(s) -
Penner Jacob,
Rupsingh Raul,
Smith Matthew,
Wells Jennie,
Borrie Michael,
Bartha Robert
Publication year - 2008
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2008.05.1132
Subject(s) - hippocampus , galantamine , creatine , phosphocreatine , glutamate receptor , metabolite , endocrinology , medicine , acetylcholine , neurotransmitter , chemistry , alzheimer's disease , donepezil , central nervous system , dementia , disease , receptor , energy metabolism
activation in Cs at z 2.26, whereas AD-Rs were comparable at z 1.82 and AD-NRs at z 0.92. Voxel-by-voxel Mann-Whitney tests (p .05) revealed Cs had significantly more activation than AD and AD-NRs in task-specific frontal and parietal areas with frontal areas being most prominently different. Cs and AD-Rs were not significantly different but AD-Rs showed significantly more activation than AD-NRs (similar to Cs). Region-of -interest Mann-Whitney tests revealed the right and left ventrolateral and medial prefrontal cortex to be more active in Cs and AD-Rs than AD-NRs, with no difference between Cs and AD-Rs. Conclusions: Differences in the fMRI activation patterns between AD-Rs and AD-NRs may predict response to cholinesterase-inhibitor treatment. Relative preservation of activation in the frontal regions of AD patients may be a biomarker reflecting the likelihood of improvement with treatment. This stratification approach could be used in future trials to define subpopulations of AD that may be amenable to treatment.